New research shows that a treatment for retinal vein occlusion yields long-lasting vision gains, with visual acuity remaining significantly above baseline at five years. However, many patients require ...

Real-world, 12-month results demonstrated efficacy, safety and durability for faricimab as a treatment for retinal vein occlusion, according to a speaker at Retina 2026.In light of faricimab’s ...

A real-world safety study found that patients treated with brolucizumab had low occurrences of intraocular inflammation, retinal vascular occlusion, and retinal vasculitis. A study published in ...

In both studies, Vabysmo was found to be noninferior to aflibercept, with average vision gains being comparable between the treatment groups. The Food and Drug Administration (FDA) has approved ...

– RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration and diabetic macular edema – – Approval is based on two Phase III studies demonstrating ...

Most of the attention within retinal research today is focused on age-related macular degeneration and diabetic retinopathy, but retinal vein occlusion is a major health problem, one physician said.

"Central Retinal Vein Occlusion Pipeline Insight"The Central Retinal Vein Occlusion (CRVO) treatment landscape is advancing, with several companies developing novel therapies to improve outcomes. CRVO ...

Retinal vascular occlusion affects the eye, specifically the retina. The retina is the light-sensitive layer of tissue that lines the back of your eye. It’s covered with special cells called rods and ...

FDA Accepts Application for Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO) ‒ Acceptance based on two Phase III studies that demonstrated early and sustained vision improvement ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Vabysmo ...